Supramolecular/Dynamic Covalent Design of High-Performance Pressure-Sensitive Adhesive from Natural Low-Molecular-Weight Compounds

Adhesive materials have played an essential role in the history of humanity. Natural adhesives composed of low-molecular-weight monomers have been overshadowed by modern petroleum-based glues. With the development of green economy, the demand for eco-friendly materials has increased. Herein, two natural biocompatible compounds, namely thioctic acid (TA) and malic acid (MA), are selected to prepare a high-performance pressure-sensitive adhesive poly[TA-MA]. This adhesive can be quantitatively obtained via a simple mixing and heating process. Poly[TA-MA] shows interesting and useful properties, including reversible flexibility, high elongation, and good self-healing, owing to its dynamic polymerization pattern and reversible cross-linking behavior. Poly[TA-MA] exhibits excellent adhesion performance under various extreme conditions, such as at low temperatures and in hot water. High values of shear strength (3.86 MPa), peel strength (7.90 N cm-1 ), loop tack (10.60 N cm-1 ), tensile strength (1.02 MPa), and shear resistance (1628 h) demonstrate the strong adhesive effect of poly[TA-MA]. Additionally, TA can be regenerated in the monomer forms from poly[TA-MA] with high recovery rate (>90%). Meanwhile, strong anti-bacterial behavior of poly[TA-MA] is recorded. This study not only reported a new pressure-sensitive adhesive but also fully displayed the feasibility of using natural small molecules to achieve robust surface adhesion.

Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment

Spinal muscular atrophy (SMA) is a lower motor neuron disease with autosomal recessive inheritance. The first cases of SMA were reported by Werdnig in 1891. Although the phenotypic variation of SMA led to controversy regarding the clinical entity of the disease, the genetic homogeneity of SMA was proved in 1990. Five years later, in 1995, the gene responsible for SMA, SMN1, was identified. Genetic testing of SMN1 has enabled precise epidemiological studies, revealing that SMA occurs in 1 of 10,000 to 20,000 live births and that more than 95% of affected patients are homozygous for SMN1 deletion. In 2016, nusinersen was the first drug approved for treatment of SMA in the United States. Two other drugs were subsequently approved: onasemnogene abeparvovec and risdiplam. Clinical trials with these drugs targeting patients with pre-symptomatic SMA (those who were diagnosed by genetic testing but showed no symptoms) revealed that such patients could achieve the milestones of independent sitting and/or walking. Following the great success of these trials, population-based newborn screening programs for SMA (more precisely, SMN1-deleted SMA) have been increasingly implemented worldwide. Early detection by newborn screening and early treatment with new drugs are expected to soon become the standards in the field of SMA.